Abbott Laboratories (ABT)
| Market Cap | 193.90B |
| Revenue (ttm) | 43.84B |
| Net Income (ttm) | 13.93B |
| Shares Out | 1.74B |
| EPS (ttm) | 7.96 |
| PE Ratio | 14.01 |
| Forward PE | 20.15 |
| Dividend | $2.52 (2.26%) |
| Ex-Dividend Date | Jan 15, 2026 |
| Volume | 15,337,377 |
| Open | 107.53 |
| Previous Close | 120.73 |
| Day's Range | 105.78 - 114.00 |
| 52-Week Range | 105.78 - 141.23 |
| Beta | 0.72 |
| Analysts | Strong Buy |
| Price Target | 147.56 (+32.33%) |
| Earnings Date | Jan 22, 2026 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2025, Abbott Laboratories's revenue was $44.33 billion, an increase of 5.67% compared to the previous year's $41.95 billion. Earnings were $6.52 billion, a decrease of -51.13%.
Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for ABT stock is "Strong Buy." The 12-month stock price target is $147.56, which is an increase of 32.33% from the latest price.
News
Cramer's Mad Dash: Abbott Labs
CNBC's Jim Cramer delivers his daily Mad Dash.
Abbott Labs Stock Hits 52-Week Low As Outlook Disappoints
Abbott Laboratories (NYSE: ABT) stock fell on Thursday after the company reported fourth-quarter 2025 sales and the first-quarter 2026 earnings outlook below expectations.
Abbott Stock Slumps on Earnings. What's Weighing on the Medical Devices Maker.
Abbott reports fourth-quarter sales that miss analysts' estimates.
Abbott misses quarterly revenue estimates on weakness in diagnostics segment
Abbott missed Wall Street estimates for quarterly revenue on Thursday, hit by weakness in its diagnostic business which has been volatile due to sharp decline in COVID-19 testing demand and a freeze o...
Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percent Full-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 perc...
Top Wall Street Forecasters Revamp Abbott Expectations Ahead Of Q4 Earnings
Abbott Laboratories (NYSE: ABT) will release earnings for the fourth quarter before the opening bell on Thursday, Jan. 22.
Polen Focus Growth Portfolio Q4 2025 Performance, Attribution & Portfolio Activity
Eli Lilly's stock price has underperformed this year, much of it on the back of drug pricing concerns, potential tariff impacts and, perhaps, less enthusiasm for GLP-1 drugs. The primary drag for the ...
Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms
Abbott's TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, is designed with dual-energy to treat atrial fibrillation patients with the most challenging cases It can deliver both radiofrequency energy...
Abbott Laboratories: Q4 Earnings On The Horizon
Abbott Laboratories has been essentially flat over the last 15 months, underperforming the S&P 500's 17.5% total return. Q3 2025 results showed normalized EPS in line at $1.30, with revenue up nearly ...
Abbott: Not Cheap, But Built To Compound In Uncertain Markets
Abbott Laboratories is a defensive, high-quality compounder with a premium valuation justified by recurring cash flow and strong medical device platforms. Medical Devices, especially Diabetes Care (Li...
Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy
The two properties strengthen the Company's presence in Illinois, where it currently owns and manages three other properties. LAS VEGAS, NEVADA / ACCESS Newswire / January 7, 2026 / Sentinel Net Lease...
Abbott hosts conference call for fourth-quarter earnings
ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2025 financial results on Thursday, Jan. 22, before the market opens.
Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions
Traditional food logging apps offer feedback after the fact—Libre Assist1 offers help in-the-moment to inform mealtime decisions before every bite Libre Assist1 leverages AI to predict how food choice...
Best Dividend Aristocrats For January 2026
The ProShares S&P 500 Dividend Aristocrat ETF (NOBL) underperformed SPY in 2025, gaining 7.2% versus SPY's 18.42%. Despite average underperformance, select Aristocrats like CAH (+74.18%), ALB (+66.90%...
Best Dividend Kings: December 2025
Dividend Kings underperformed SPY in 2025, up 4.47% vs. SPY's 17.7%, but select Kings outperformed the index. Twenty-two Dividend Kings are identified as both potentially undervalued and offering long...
Chevron, Kimberly-Clark Among 16 Companies To Kick Off 2026 With Annual Dividend Increases In January
Chevron (CVX) is expected to extend its dividend growth streak to 39 years, but with a muted 3–4% increase amid lower oil prices. CVX's earnings remain under pressure from declining oil prices despite...
Abbott Laboratories Shrugs Off Tariffs And China Headwinds With A 7% Dividend Raise
Abbott Laboratories (ABT) earns a buy rating for its operational resilience, robust fundamentals, and strong dividend growth despite headwinds. ABT delivered double-digit EPS growth, solid Medical Dev...
Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation
Abbott's Volt™ PFA System, the latest generation of cardiac ablation technology, is designed for people battling heart rhythm disorders such as atrial fibrillation (AFib) Pulsed field ablation – or PF...
Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart
First and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart New delivery system enables precise placemen...
Abbott increases quarterly dividend for 54th consecutive year
Quarterly dividend increased by 6.8% Quarterly dividend payout has increased more than 70% since 2020 408th consecutive quarterly dividend to be paid by Abbott since 1924 ABBOTT PARK, Ill., Dec. 12, 2...
High-Quality Compounders With Both Pricing Power And Idiosyncratic Growth
The Touchstone Mid Cap Growth Fund outperformed its benchmark, the Russell Midcap® Growth Index, for the quarter ended September 30, 2025. From a factor perspective, the Fund's overweight exposure to ...
Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data
Lingo, Abbott's first over-the-counter biowearable, expands to Android devices Continuous glucose monitoring devices help people maintain healthy glucose levels, which are associated with better metab...
University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives
University of Wisconsin wins Abbott and the Big Ten Conference's "We Give Blood" drive, awards $1 million from Abbott to advance student or community health Second year of nationwide blood drive saw a...
Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement
Aging, nutrition and lifestyle affect muscles, especially after age 40. That's why Matt Ryan, former professional quarterback and MVP, is teaming up with Abbott to drive muscle health awareness with t...
Best Dividend Aristocrats For December 2025
The ProShares S&P 500 Dividend Aristocrats ETF (NOBL) has underperformed the SPDR S&P 500 ETF (SPY) year-to-date, but November shows a reversal. Several Dividend Aristocrats, including CAH, CAT, CHRW,...